Beyond the Acute Phase: Long-Term Impact of COVID-19 on Functional Capacity and Prothrombotic Risk—A Pilot Study

Background and Objectives: Assessment of the prothrombotic, proinflammatory, and functional status of a cohort of COVID-19 patients at least two years after the acute infection to identify parameters with potential therapeutic and prognostic value. Materials and Methods: We conducted a retrospective, descriptive study that included 117 consecutive patients admitted to Iasi Pulmonary Rehabilitation Clinic for reassessment and a rehabilitation program at least two years after a COVID-19 infection. The cohort was divided into two groups based on the presence (n = 49) or absence (n = 68) of pulmonary fibrosis, documented through high-resolution computer tomography. Results: The cohort comprises 117 patients, 69.23% females, with a mean age of 65.74 ± 10.19 years and abnormal body mass index (31.42 ± 5.71 kg/m2). Patients with pulmonary fibrosis have significantly higher levels of C-reactive protein (CRP) (p < 0.05), WBC (7.45 ± 7.86/mm3 vs. 9.18 ± 17.24/mm3, p = 0.053), neutrophils (4.68 ± 7.88/mm3 vs. 9.07 ± 17.44/mm3, p < 0.05), mean platelet volume (MPV) (7.22 ± 0.93 vs. 10.25 ± 0.86 fL, p < 0.05), lactate dehydrogenase (p < 0.05), and D-dimers (p < 0.05), but not ferritin (p = 0.470), reflecting the chronic proinflammatory and prothrombotic status. Additionally, patients with associated pulmonary fibrosis had a higher mean heart rate (p < 0.05) and corrected QT interval (p < 0.05). D-dimers were strongly and negatively correlated with diffusion capacity corrected for hemoglobin (DLCO corr), and ROC analysis showed that the persistence of high D-dimers values is a predictor for low DLCO values (ROC analysis: area under the curve of 0.772, p < 0.001). The results of pulmonary function tests (spirometry, body plethysmography) and the 6-minute walk test demonstrated no significant difference between groups, without notable impairment within either group. Conclusions: Patients with COVID-19-related pulmonary fibrosis have a persistent long-term proinflammatory, prothrombotic status, despite the functional recovery. The persistence of elevated D-dimer levels could emerge as a predictive factor associated with impaired DLCO.

[1]  B. Patel,et al.  Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States , 2023, Lancet regional health. Americas.

[2]  M. Marc,et al.  Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study , 2023, Journal of personalized medicine.

[3]  Carlos M. Morel,et al.  Hematological alterations associated with long COVID-19 , 2023, Frontiers in physiology.

[4]  M. Wygrecka,et al.  Decoding the role of fatty acids and their metabolites in lung fibrosis. , 2023, Polish archives of internal medicine.

[5]  J. Dai,et al.  Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy , 2023, Journal of Molecular Medicine.

[6]  S. Duong-Quy,et al.  Post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review , 2023, Pulmonary Therapy.

[7]  K. Stark,et al.  Thromboinflammation in long COVID—the elusive key to postinfection sequelae? , 2023, Journal of Thrombosis and Haemostasis.

[8]  S. Parthasarathy,et al.  Long COVID: a review and proposed visualization of the complexity of long COVID , 2023, Frontiers in Immunology.

[9]  I. Pavord,et al.  Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary , 2023, Respirology.

[10]  E. Topol,et al.  Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.

[11]  P. Durrington Blood lipids after COVID-19 infection , 2023, The Lancet Diabetes & Endocrinology.

[12]  M. Wygrecka,et al.  Diverse Functions of Apolipoprotein A-I in Lung Fibrosis. , 2022, American journal of physiology. Cell physiology.

[13]  V. Tsampasian,et al.  Post-COVID-19 syndrome risk factors and further use of health services in East England , 2022, PLOS global public health.

[14]  W. Man,et al.  A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae , 2022, Science Translational Medicine.

[15]  N. C. Cimşit,et al.  New grading system for post-COVID-19 pulmonary fibrosis based on computed tomography findings , 2022, Medicine.

[16]  S. Tanni,et al.  Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We? , 2022, Archivos de Bronconeumología.

[17]  Rui A. Lima,et al.  Diagnosis Methods for COVID-19: A Systematic Review , 2022, Micromachines.

[18]  X. Wang,et al.  Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study , 2022, Science bulletin.

[19]  S. Saydah,et al.  Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021 , 2022, Morbidity and Mortality Weekly Report.

[20]  I. Mitroulis,et al.  Editorial: Platelet Function in COVID-19 , 2022, Frontiers in Cardiovascular Medicine.

[21]  Arthur L. Allen,et al.  Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum , 2022, Journal of Thrombosis and Thrombolysis.

[22]  Laura Schneider,et al.  Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults , 2022, Frontiers in Neurology.

[23]  J. Gonzales-Zamora,et al.  Mean Platelet Volume as a Predictor of COVID-19 Severity: A Prospective Cohort Study in the Highlands of Peru , 2022, Diseases.

[24]  V. Novakovic,et al.  Persistent Lung Injury and Prothrombotic State in Long COVID , 2022, Frontiers in Immunology.

[25]  V. Novakovic,et al.  Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation , 2022, Frontiers in Cellular and Infection Microbiology.

[26]  P. Bonniaud,et al.  Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis , 2022, Cells.

[27]  C. Fernández‐de‐las‐Peñas,et al.  Long COVID: systemic inflammation and obesity as therapeutic targets , 2022, The Lancet Respiratory Medicine.

[28]  R. Otero-Candelera,et al.  Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases , 2022, Archivos de Bronconeumología.

[29]  F. Kakamad,et al.  Post COVID-19 pulmonary fibrosis; a meta-analysis study , 2022, Annals of Medicine and Surgery.

[30]  E. Ponomarev,et al.  Meta-Analysis and Systematic Review of Coagulation Disbalances in COVID-19: 41 Studies and 17,601 Patients , 2022, Frontiers in Cardiovascular Medicine.

[31]  V. Poletti,et al.  European Respiratory Society statement on long COVID follow-up , 2022, European Respiratory Journal.

[32]  Benjamin Bowe,et al.  Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.

[33]  Nelson B Rodrigues,et al.  Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis , 2021, Brain, Behavior, and Immunity.

[34]  S. Stanojevic,et al.  ERS/ATS technical standard on interpretive strategies for routine lung function tests , 2021, European Respiratory Journal.

[35]  H. Hackl,et al.  Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype , 2021, Frontiers in Cardiovascular Medicine.

[36]  A. Zoufaly,et al.  Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5 , 2021, Frontiers in Cardiovascular Medicine.

[37]  F. Bai,et al.  Female gender is associated with long COVID syndrome: a prospective cohort study , 2021, Clinical Microbiology and Infection.

[38]  G. Poudel,et al.  Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection , 2021, JAMA network open.

[39]  S. Tanni,et al.  Pulmonary fibrosis and follow-up of COVID-19 survivors: an urgent need for clarification , 2021, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[40]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[41]  T. Renné,et al.  Persistent endotheliopathy in the pathogenesis of long COVID syndrome , 2021, Journal of Thrombosis and Haemostasis.

[42]  E. Poveda,et al.  Long COVID in hospitalized and non-hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study , 2021, Scientific Reports.

[43]  F. Dioguardi,et al.  Serum Metabolic Profile in Patients With Long-Covid (PASC) Syndrome: Clinical Implications , 2021, Frontiers in Medicine.

[44]  E. Hoffman,et al.  Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length , 2021, Thorax.

[45]  A. Fabro,et al.  Pulmonary fibrosis secondary to COVID-19: a narrative review , 2021, Expert review of respiratory medicine.

[46]  S. Plíšek,et al.  Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia , 2021, Virology journal.

[47]  A. Bellasi,et al.  Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation , 2021, Epidemiology and Infection.

[48]  F. Kronenberg,et al.  Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial , 2020, European Respiratory Journal.

[49]  R. Sutton,et al.  Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. , 2020, Clinical medicine.

[50]  Arthur S Slutsky,et al.  Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19 , 2020, Canadian Medical Association Journal.

[51]  C. Campèse,et al.  First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[52]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[53]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[54]  Thomas Kahan,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[55]  Bertram L Kasiske,et al.  Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). , 2011, Kidney international.

[56]  R Merget,et al.  Body plethysmography--its principles and clinical use. , 2011, Respiratory medicine.

[57]  Kannan Ramar,et al.  Updates on definition, consequences, and management of obstructive sleep apnea. , 2011, Mayo Clinic proceedings.

[58]  A. Chetta,et al.  Reference values for the 6-min walk test in healthy subjects 20-50 years old. , 2006, Respiratory medicine.